PDSB — PDS Biotechnology Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1472091 ·
Last close
$0.80
Market Cap
$44.61M
52W High
$1.55
52W Low
$0.19
ADV30
43,933,077
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -6,496,734 | -9,750,575 | 8,807,213 | 5,596,254 | 12,386,952 |
| Mar 2026 | 0 | — | -6,521,087 | -7,349,056 | 24,663,026 | 21,660,496 | 20,770,383 |
| Dec 2025 | 0 | — | -6,674,708 | -7,562,919 | 30,494,083 | 26,711,969 | 21,242,250 |
| Sep 2025 | 0 | — | -8,140,142 | -9,009,411 | 34,705,801 | 26,198,652 | 25,252,291 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,091,402
Investing CF
$0
Financing CF
$4,773,224
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.74
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-223,955,560
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-27,933,082
Pretax Income TTM
$-33,355,594
Interest Exp TTM
$5,422,512
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -31,543,959 | -34,495,505 | 30,494,083 | 21,242,250 | 9,251,833 | -27,752,012 |
| Dec 2024 | 0 | -36,321,195 | -37,610,384 | 45,358,657 | 26,353,809 | 19,004,848 | -35,030,223 |
| Dec 2023 | 0 | -43,045,234 | -42,942,198 | 59,390,080 | 33,259,133 | 26,130,947 | -33,636,136 |
| Dec 2022 | 0 | -41,672,421 | -40,854,855 | 77,007,923 | 33,005,893 | 44,002,030 | -25,709,706 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.36
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $0.80 · call volume: 1,058 · put volume: 1,501
Expected Move to 2026-11-20:
±$0.48
(60.23%) —
implied range
$0.32 –
$1.28
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GRCE | Grace Therapeutics, Inc. | $44.60M | $2.12 | — |
| SCYX | SCYNEXIS INC | $43.68M | $4.39 | — |
| VERU | VERU INC. | $43.31M | $2.54 | — |
| DWTX | Dogwood Therapeutics, Inc. | $46.23M | $1.36 | — |
| HOWL | Werewolf Therapeutics, Inc. | $46.66M | $0.96 | — |
News headlines (Yahoo Finance, 1h cache)
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncolog
2026-09-22 12:00 · Yahoo
PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny
2026-09-18 21:12 · Yahoo
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
2026-09-14 14:30 · Yahoo
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
2026-09-08 12:30 · Yahoo
PDS Biotech Reports Second Quarter 2026 Financial Results
2026-08-13 12:30 · Yahoo
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
2026-06-10 13:55 · Yahoo
PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...
2026-05-13 23:02 · Yahoo
PDS Biotechnology Q1 Earnings Call Highlights
2026-05-13 18:09 · Yahoo
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
2026-05-13 11:00 · Yahoo
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
2026-05-13 12:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.